Skip to main content
Top
Published in: Diabetologia 8/2019

01-08-2019 | Ramipril | Review

Does diabetes prevention translate into reduced long-term vascular complications of diabetes?

Authors: David M. Nathan, Peter H. Bennett, Jill P. Crandall, Sharon L. Edelstein, Ronald B. Goldberg, Steven E. Kahn, William C. Knowler, Kieren J. Mather, Sunder Mudaliar, Trevor J. Orchard, Marinella Temprosa, Neil H. White, and the DPP Research Group

Published in: Diabetologia | Issue 8/2019

Login to get access

Abstract

The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development. A variety of interventions, including lifestyle modifications and pharmacological agents directed at ameliorating the major risk factors for type 2 diabetes, are of proven efficacy in reducing the development of type 2 diabetes in people with impaired glucose tolerance. While prevention of the hyperglycaemia characteristic of diabetes is arguably an important, clinically relevant outcome, a more compelling outcome with greater clinical significance is the prevention or reduction of the relatively diabetes-specific microvascular and less-specific cardiovascular disease (CVD) complications associated with diabetes. These complications cause the majority of morbidity and excess mortality associated with diabetes. Any reduction in diabetes should, logically, also reduce the occurrence of its long-term complications; however, most diabetes prevention trials have not been of sufficient duration to allow such an evaluation. The limited long-term data, largely from the Da Qing Diabetes Prevention Study (DQDPS) and the Diabetes Prevention Program (DPP) and their respective follow-up studies (DQDPOS and DPPOS), suggest a reduction in microvascular complications and amelioration of CVD risk factors. Only the DQDPOS and Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) studies have shown a reduction in CVD events and only DQDPOS has demonstrated a decrease in CVD and overall mortality. While these limited data are promising, whether diabetes prevention directly reduces complication-related morbidity and mortality remains unclear. Longer follow-up of prevention studies is needed to supplement the limited current clinical trial data, to help differentiate the effects of diabetes prevention itself from the means used to reduce diabetes development and to understand the balance among benefits, risks and costs of prevention.
Appendix
Available only for authorised users
Literature
3.
go back to reference Rosenquist KJ, Fox CS Mortality trends in type 2 diabetes. In: Cowie CC, Casagrande SS, Menke A et al (eds) Diabetes in America, 3rd edn. National Institutes of Health, Bethesda, pp 36.1–36.14 Rosenquist KJ, Fox CS Mortality trends in type 2 diabetes. In: Cowie CC, Casagrande SS, Menke A et al (eds) Diabetes in America, 3rd edn. National Institutes of Health, Bethesda, pp 36.1–36.14
6.
go back to reference Knowler WC, Crandall JP, Chiasson J-L, Nathan DM Prevention of diabetes. In: Cowie CC, Casagrande SS, Menke A et al (eds) Diabetes in America, 3rd edn. National Institutes of Health, Bethesda, pp 38.1–38.21 Knowler WC, Crandall JP, Chiasson J-L, Nathan DM Prevention of diabetes. In: Cowie CC, Casagrande SS, Menke A et al (eds) Diabetes in America, 3rd edn. National Institutes of Health, Bethesda, pp 38.1–38.21
13.
go back to reference Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCentral Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCentral
14.
go back to reference Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcome Study. Lancet Diabetes Endocrinol 3:866–875PubMedCentral Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcome Study. Lancet Diabetes Endocrinol 3:866–875PubMedCentral
16.
go back to reference Diabetes Prevention Program Outcomes Study Research Group (2013) Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 30:46–55 Diabetes Prevention Program Outcomes Study Research Group (2013) Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 30:46–55
19.
go back to reference Goldberg RB, Temprosa M, Haffner S et al (2009) Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 32(4):726–732. https://doi.org/10.2337/dc08-0494 CrossRefPubMedPubMedCentral Goldberg RB, Temprosa M, Haffner S et al (2009) Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 32(4):726–732. https://​doi.​org/​10.​2337/​dc08-0494 CrossRefPubMedPubMedCentral
22.
go back to reference NAVIGATOR Study Group (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476 NAVIGATOR Study Group (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476
23.
go back to reference NAVIGATOR Study Group (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490 NAVIGATOR Study Group (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490
27.
go back to reference DREAM Trial Investigators (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562 DREAM Trial Investigators (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562
28.
go back to reference DREAM Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 358:1096–1105 DREAM Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 358:1096–1105
29.
go back to reference Dagenais GR, Gerstein HC, Holman R et al (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial. Diabetes Care 31(5):1007–1014. https://doi.org/10.2337/dc07-1868 CrossRefPubMed Dagenais GR, Gerstein HC, Holman R et al (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial. Diabetes Care 31(5):1007–1014. https://​doi.​org/​10.​2337/​dc07-1868 CrossRefPubMed
33.
go back to reference ORIGIN Trial Investigators (2014) Basal insulin glargine and microvascular outcomes in dysglycemic individuals: results of the Outcome Reduction with an initial Glargine Intervention (ORIGIN) trial. Diabetologia 57:1325–1331 ORIGIN Trial Investigators (2014) Basal insulin glargine and microvascular outcomes in dysglycemic individuals: results of the Outcome Reduction with an initial Glargine Intervention (ORIGIN) trial. Diabetologia 57:1325–1331
39.
go back to reference DCCT/EDIC Research Group (2016) Risk factors for cardiovascular disease in type 1 diabetes. Diabetes 65:1370–1379 DCCT/EDIC Research Group (2016) Risk factors for cardiovascular disease in type 1 diabetes. Diabetes 65:1370–1379
Metadata
Title
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Authors
David M. Nathan
Peter H. Bennett
Jill P. Crandall
Sharon L. Edelstein
Ronald B. Goldberg
Steven E. Kahn
William C. Knowler
Kieren J. Mather
Sunder Mudaliar
Trevor J. Orchard
Marinella Temprosa
Neil H. White
and the DPP Research Group
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4928-8

Other articles of this Issue 8/2019

Diabetologia 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.